Skip to main navigation

Careers

About Us
Scientific Focus

Our Focus

Our Platform Technologies:
Turbo-ZM™ RMAs / ERSGs
Class 1 CF
Pipeline

Pipeline

Class 1 CF

RDEB/JEB

FAP & CRC
Scientific Documents
Investors

Overview

Press Releases

Events & Presentations

Corporate Governance

Financials and Filings

Stock Information

Analyst Coverage

Investment Inquiries

Press Releases

Overview
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investment Inquiries

Year

Eloxx Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome with First Patient Dosed

February 27, 2023

Eloxx Pharmaceuticals Announces First Patients Enrolled in Phase 2 Clinical Study Evaluating ELX-02 for the Treatment of Alport Syndrome

January 25, 2023

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 22 of 22

TURBO-ZM is a trademark of Eloxx Pharmaceuticals, Inc..
©2023 Eloxx Pharmaceuticals, Inc.
Produced in the USA.
November 2023

Privacy Policy | Contact Us